In this regard, we note that Abbott has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, widely known as the FreeStyle Libre System. This is likely to have majorly contributed to the company's fourth-quarter performance. In the United States, the company initiated the full launch of Libre 3, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. Abbott Laboratories Price and EPS SurpriseĮxcluding COVID testing revenues, sales of routine diagnostic tests are expected to have improved in Q4 on the continuous rollout of Alinity, Abbott’s suite of diagnostic instruments, as well as expanding menus across the company’s testing platforms of immunoassay, clinical chemistry and molecular testing.Ībbott’s other consumer-facing businesses, which include diabetes care, have been catching up, backed by new product instructions. The fourth-quarter performance is likely to have been driven by growing customer demand for core therapeutic lines, including cardiometabolic, respiratory and central nervous system/pain management. New product launches across key markets have been majorly boosting the EPD business in recent months. On a positive note, within Established Pharmaceuticals Division (EPD), the company has been witnessing visible signs of a rebound, reflecting sequential improvement based on its stable business model. The lockdown issues in limited geographies, including China where the company has extensive base, are expected to have also impacted business during the fourth quarter. Not just this, the existing healthcare staffing challenges and diminishing demand for COVID-testing products may also have weighed on the company through the Q4 months. Going by the industry-wide trend so far, logistical challenges and increasing unit cost might have weighed on corporate profitability of the company. dollar and supply chain issues in certain areas of business, most notably, in Electrophysiology are expected to have adversely impacted Abbott’s overall fourth-quarter performance. Stubborn inflationary pressure, record strengthening of the U.S. Let's see how things have shaped up prior to this announcement. Over the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all the occasions, the average beat being 21.78%. In the last reported quarter, the company delivered an earnings surprise of 26.37%. Abbott Laboratories ABT is slated to report fourth-quarter 2022 results on Jan 25, before market open.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |